CalciMedica, Inc. Common Stock - Asset Resilience Ratio
CalciMedica, Inc. Common Stock (CALC) has an Asset Resilience Ratio of 11.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how CalciMedica, Inc. Common Stock's Asset Resilience Ratio has changed over time. Check CalciMedica, Inc. Common Stock (CALC) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down CalciMedica, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is CalciMedica, Inc. Common Stock worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 11.01% |
| Total Liquid Assets | $1.50 Million | 11.01% |
Asset Resilience Insights
- Moderate Liquidity: CalciMedica, Inc. Common Stock has 11.01% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
CalciMedica, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare CalciMedica, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for CalciMedica, Inc. Common Stock (2019–2025)
The table below shows the annual Asset Resilience Ratio data for CalciMedica, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.01% | $1.50 Million | $13.59 Million | -43.22pp |
| 2024-12-31 | 54.23% | $10.73 Million | $19.79 Million | +7.38pp |
| 2023-12-31 | 46.84% | $5.71 Million | $12.19 Million | -25.97pp |
| 2021-12-31 | 72.81% | $50.31 Million | $69.09 Million | +12.29pp |
| 2020-12-31 | 60.53% | $61.62 Million | $101.79 Million | +11.13pp |
| 2019-12-31 | 49.40% | $20.09 Million | $40.66 Million | -- |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxi… Read more